Oculis Holding AG (OCS)

NASDAQ
7.430
-0.270(-3.51%)
  • Volume:
    3,323
  • Day's Range:
    7.410 - 7.700
  • 52 wk Range:
    6.260 - 14.100

OCS Overview

Prev. Close
7.7
Day's Range
7.41-7.7
Revenue
-
Open
7.7
52 wk Range
6.26-14.1
EPS
-12.94
Volume
3,323
Market Cap
243.21M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
127,653
P/E Ratio
-0.544
Beta
0.03
1-Year Change
-23.72%
Shares Outstanding
32,733,373
Next Earnings Date
-
What is your sentiment on Oculis Holding?
or
Market is currently closed. Voting is open during market hours.

Oculis Holding AG Company Profile

Oculis Holding AG Company Profile

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops novel topical treatments for ophthalmic diseases for both back- and front-of-the-eye. The company’s lead candidate is OCS-01, a topical dexamethasone formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for keratoconjunctivitis sicca, or dry eye disease; and OCS-05, a novel neuroprotective agent for acute optic neuritis and other neuro-ophtha disorders, such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The company is based in Zug, Switzerland.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellStrong SellStrong SellStrong SellSell
Technical IndicatorsStrong SellStrong SellStrong SellStrong SellNeutral
SummaryStrong SellStrong SellStrong SellStrong SellNeutral